Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$1.45
-0.3%
$1.40
$1.05
$5.17
$155.93M0.381.21 million shs402,410 shs
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$13.72
-0.3%
$13.96
$7.86
$17.75
$1.65B1.772.20 million shs778,148 shs
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$19.08
$24.33M0.4123,145 shs237,144 shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$0.84
-1.4%
$1.00
$0.69
$4.99
$39.92M1.63331,128 shs94,167 shs
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$11.19
+1.2%
$10.16
$7.44
$11.82
$557.52M-0.02267,541 shs65,540 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
0.00%-1.70%-10.25%+3.21%+25.65%
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.00%-0.18%+3.35%-6.89%+42.86%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%0.00%+10.83%+62.99%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
0.00%-2.19%-28.02%+13.92%-77.43%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
0.00%-0.31%+1.59%+32.52%+31.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
2.4265 of 5 stars
3.62.00.00.01.91.70.6
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.0656 of 5 stars
3.41.00.00.02.21.70.6
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.3513 of 5 stars
0.00.00.04.20.60.80.0
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.8611 of 5 stars
3.44.00.00.00.61.71.3
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.0817 of 5 stars
3.30.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.11
Buy$9.71572.27% Upside
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.83
Moderate Buy$18.8037.08% Upside
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00
N/AN/AN/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.83
Moderate Buy$7.50798.20% Upside
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.67
Moderate Buy$16.6048.41% Upside

Current Analyst Ratings Breakdown

Latest ACRS, CARA, ARQT, TBPH, and STTK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $25.00
6/25/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/23/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
6/17/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$24.00
5/28/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$8.00
5/23/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
5/14/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $16.00
5/9/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00
4/9/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$18.72M8.36N/AN/A$1.44 per share1.00
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$196.54M8.32N/AN/A$1.35 per share10.16
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$5.72M6.99N/AN/A$1.67 per share0.50
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$64.38M8.69N/AN/A$3.57 per share3.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/13/2025 (Estimated)
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$75.41M-$1.39N/AN/AN/AN/A-79.69%-69.13%7/30/2025 (Estimated)
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$56.42M-$1.18N/A31.96N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)

Latest ACRS, CARA, ARQT, TBPH, and STTK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million
5/6/2025Q1 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A
5/6/2025Q1 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million
5/1/2025Q1 2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.29-$0.27+$0.02-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
5.06
5.06
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.75
3.55
3.37
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/A
9.08
9.08
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/A
4.77
4.77
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100108.28 million101.35 millionOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150119.20 million108.00 millionOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10047.90 million42.15 millionOptionable
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
35950.00 million46.55 millionOptionable

Recent News About These Companies

TBPH Theravance Biopharma, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$1.44 -0.01 (-0.34%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.44 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$13.72 -0.05 (-0.33%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$13.72 0.00 (0.00%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Shattuck Labs stock logo

Shattuck Labs NASDAQ:STTK

$0.84 -0.01 (-1.42%)
As of 07/3/2025 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Theravance Biopharma stock logo

Theravance Biopharma NASDAQ:TBPH

$11.18 +0.14 (+1.22%)
Closing price 07/3/2025 01:21 PM Eastern
Extended Trading
$11.18 0.00 (0.00%)
As of 07/3/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.